{Reference Type}: Journal Article
{Title}: The antimicrobial effectiveness of chlorhexidine and chlorhexidine-silver sulfadiazine impregnated central venous catheters against the emerging fungal pathogen Candida auris.
{Author}: Gupta N;Haughton S;Kemper S;Koehler M;Antoon R;Edwards CG;Bardin A;
{Journal}: Am J Infect Control
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 27
{Factor}: 4.303
{DOI}: 10.1016/j.ajic.2024.06.015
{Abstract}: <B>BACKGROUND: </B>Candida auris is an emerging multidrug-resistant fungus associated with catheter-related bloodstream infections (CRBSI). In-vitro efficacy of chlorhexidine (CHX) and CHX/silver sulfadiazine-impregnated (CHX-S) antimicrobial central venous catheters (CVCs) against C. auris was investigated.<BR><B>METHODS: </B>Minimum inhibitory (MIC) and bactericidal (MBC) CHX concentrations were determined against nineteen C. auris isolates. To assess extraluminal efficacy, segments from CVCs impregnated externally (CHX-S1) and both externally and internally (CHX-S2) were plasma-conditioned for 1- and 6-days, and to assess intraluminal efficacy CHX-S2 CVCs were pre-conditioned with saline-lock for 6-days, followed by 24-hour C. auris inoculation and microbial adherence determination on impregnated and non-impregnated CVCs.<BR><B>RESULTS: </B>CHX inhibited all C. auris isolates with MIC and MBC range of 8-128 μg/mL. C. auris adherence was reduced on CHX-S1 and CHX-S2 extraluminally by 100% on day-1, 86.96%-100% on day-7, and intraluminally on CHX-S2 by 56.86%-90.52% on day-7.<BR><B>CONCLUSIONS: </B>CHX and CHX-S CVCs performance against C. auris observed in this study is consistent with antimicrobial benefits observed in prior pre-clinical and randomized controlled clinical studies.<BR><B>CONCLUSIONS: </B>CHX showed strong inhibitory and cidal effects on C. auris. CHX-S CVCs proved highly efficacious against this pathogen under in vitro conditions. Additional studies, however, are required to confirm clinical benefit.